Rachel Grisham, MD
Memorial Sloan Kettering Cancer Center · GOG Foundation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rachel Grisham, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:22 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06394804 · A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerMemorial Sloan Kettering Cancer Center · recruiting · Low-Grade Serous Ovarian Cancer · principal investigator
- Ph2NCT06240598 · A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of ChemotherapyMemorial Sloan Kettering Cancer Center · active not recruiting · Ovarian Cancer · principal investigator
- Ph3NCT06072781 · A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerVerastem, Inc. · recruiting · Low Grade Serous Ovarian Cancer · principal investigator
- Ph2NCT05787561 · A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerMemorial Sloan Kettering Cancer Center · active not recruiting · Mesonephric Gynecologic Cancer · principal investigator
- Ph2NCT04625270 · A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS MutationVerastem, Inc. · active not recruiting · Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer · principal investigator
- Ph2NCT03909152 · A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to ProgesteroneMemorial Sloan Kettering Cancer Center · completed · Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer · principal investigator
- Ph2NCT01974765 · Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior TherapiesMemorial Sloan Kettering Cancer Center · completed · Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.